GSK plc (BCBA:GSK)
Argentina · Delayed Price · Currency is ARS | Market Cap | 151.86T +29.0% |
| Revenue (ttm) | 65.27T +5.0% |
| Net Income | 9.48T +40.8% |
| EPS | 2,316.42 +42.6% |
| Shares Out | n/a |
| PE Ratio | 16.03 |
| Forward PE | 10.04 |
| Dividend | 592.66 (2.97%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 115 |
| Open | 20,110 |
| Previous Close | 20,250 |
| Day's Range | 19,920 - 20,270 |
| 52-Week Range | 13,680 - 22,760 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsNews
GSK Bets on Long-Acting Biologics and AI to Reshape Respiratory Care
GSK NYSE: GSK is advancing a respiratory and immunology pipeline centered on longer-acting biologics, more targeted patient selection and combination approaches, according to Kaivan Khavandi, the comp...
GSK plc Transcript: Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
The forum highlighted a robust pipeline in respiratory, immunology, and metabolic diseases, with a focus on ultra-long-acting biologics, novel mechanisms, and data-driven patient stratification. AI and global partnerships, especially in China, are accelerating development, while external innovation and M&A remain key to pipeline expansion.
GSK Targets £40B Sales as Oncology Push and £1.9B Savings Plan Take Shape
GSK NYSE: GSK Chief Financial Officer Julie Brown outlined the company's growth strategy, launch priorities and cost-savings plans during a discussion with Bank of America analyst Sachin Jain followin...
GSK plc Transcript: Bank of America Global Healthcare Conference
Management outlined a GBP 1.9 billion self-funded savings plan to accelerate growth, prioritize oncology, and support margin stability through 2030. Key launches like Excentia, BLENREP, and bepirovirsen are expected to drive future growth, while headwinds include TRELEGY IRA impacts and base effects on established products.
European drugmakers call for faster trials, more spending to compete with US, China
European drugmakers called for beefed-up government spending on medicines, faster trials and IP protections as they sounded warnings on Tuesday that the continent's pharmaceutical industry risks los...
Broker Tips: Bytes Technology, AstraZeneca, GSK, WH Smith, Man Group
Broker tips for UK stocks that have caught our eye over the last week include Bytes Technology, AstraZeneca, GSK, WH Smith and Man Group
GSK Passive Income Stock Makes the August ISA Top 10 Despite Patent Headwinds
GSK (LSE: GSK) has been appearing regularly as a passive income stock in the August top-ten most-bought lists on popular ISA platforms, and the reasons for that investor interest hold up under scrutin...
Re-entering the Dragon: GSK returns to China after 12 years in blood cancer drug push
What a difference 12 years make. In 2014 GlaxoSmithKline was fined £300m by a Chinese court for running a 'massive bribery network'.
Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead
(RTTNews) - Biotech investors tracked a busy week marked by regulatory approvals, strategic collaborations, workforce restructuring and key clinical trial readouts.
FENI, GSK, HSBC, SHEL: Large Inflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Fidelity Enhanced International ETF (Symbol: FENI) where we have detec...
ViiV Healthcare continues partnership with Prevention Access Campaign
ViiV Healthcare, the global specialist HIV company majority owned by GSK (GSK), with Shionogi as a shareholder, announced the continuation of its long-standing partnership with Prevention Access Campa...
GSK Targets Oncology Growth With Lung, Prostate and Gynecologic Cancer Pipeline
GSK NYSE: GSK is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung cancer, gastrointestinal cancers and prostate cancer, with a combination of inte...
GSK Targets Oncology Growth With Lung, Prostate and Gynecologic Cancer Pipeline
MarketBeat Week in Review – 06/08 - 06/12GSK (NYSE:GSK) is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung cancer, gastrointestinal cancers and p...
GSK licenses Chinese firm’s cancer drug in US$750 million deal
British pharmaceutical giant GSK has agreed to acquire a cancer drug from Chinese firm Chimagen Biosciences in a deal worth up to US$750 million, underscoring China’s emergence as a global player in b...
GSK plc at Morgan Stanley Global Healthcare Conference Transcript
GSK plc at Morgan Stanley Global Healthcare Conference Transcript
GSK plc Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The oncology portfolio has rapidly expanded through focused internal R&D and strategic acquisitions, with key assets like B7-H3, B7-H4, neladalkib, and zidesamtinib driving growth. Robust clinical data and disciplined strategy underpin confidence in meeting ambitious 2031 sales targets.
GSK Looks 9.5% Overvalued on GF Value™ as Dividend Sustainability Remains Key
GSK Looks 9.5% Overvalued on GF Value™ as Dividend Sustainability Remains Key
GSK enters agreement to acquire trispecific TCE from Chimagen
GSK (GSK) announced it has entered an agreement to acquire a trispecific T cell-engager, TCE, from Chimagen Biosciences, a privately held biotechnology company. GSK plans to develop and commercialize ...
GSK upgraded to Buy from Hold at Berenberg
Berenberg analyst Kerry Holford upgraded GSK (GSK) to Buy from Hold with a price target of 2,200 GBp, up from 2,000 GBp. The firm is “increasingly optimistic” about GSK’s growth…
GSK Looks 9.6% Overvalued on GF Value™ as Dividend Sustainability Remains Key
GSK Looks 9.6% Overvalued on GF Value™ as Dividend Sustainability Remains Key
GSK strikes up to $750 million deal for cancer-targeting drug
GSK said on Tuesday it had agreed a deal worth up to $750 million to buy a trispecific T cell-engager (TCE), a drug designed to help T-cells target cancer, from China-based biotechnology firm Chimag...
GSK To Buy T Cell-engager For Multiple Myeloma From Chimagen Biosciences For Up To $750 Mln
(RTTNews) - British drug major GSK plc (GSK, GSK.L) announced Tuesday that it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager or TCE for multiple myeloma from ...
GSK PLC (GSK) Shares Surge 4.0% -- What GF Score of 71 Tells Investors
GSK PLC (GSK) Shares Surge 4.0% -- What GF Score of 71 Tells Investors
GSK Shares Jump 3.83% as Twin Lung Cancer Drug Trial Wins Reinforce Its Growing Oncology Pipeline Bet
GSK shares climbed after the company reported encouraging clinical trial results for two lung cancer treatments, strengthening its oncology strategy despite mixed analyst views on the stock.
GSK's Jideytro & Ris-Rez Show Positive Data In Two Lung Cancer Studies
(RTTNews) - GSK plc (GSK), a biopharmaceutical company, reported positive clinical data for two of its lung cancer medicines, with Jideytro showing high response rates in previously untreated ROS1-pos...